top of page

ANTI-SCARRING
GENE THERAPY

Mechanism of Action

Slide2.png

Expression of Genevector

Slide1.png
Expression 77 Days.jpg
Slide1.png

SCARLEXA and FIBREXA are proprietary gene vectors being developed for human use.

​

Applied in the wound (SCARLEXA) or inhaled (FIBREXA) delivers the genetic code for expression and production of anti- scarring peptides at the site of injury in skin and lungs, respectively.

​

​

​

​

Product Canditates

Scarlexa to prevent dermal scarring after burn injuries

Gene therapy for dermal application to prevent scarring after burn injury. Applied topically by spray or ointment suitable for larger body surface area.  

BurnScarjpg.jpg

Scarlexa to prevent dermal scarring after surgery

For prevention of dermal scarring after surgery, e.g. breast implant or C-section. Applied as gel before wound closure or injected subcuteneously into the wound area in cosmetically challenging areas such as the face, mammoplasty or after C-section.

Breast implant.jpg
C-section.png
DermalScar_edited.jpg

Fibrexa  for mitigation of respiratory infections

FIBREXA  is a formulation for inhalation by high risk patients e.g. elderly or other patients with risk factors for developing long-term complications with fibrosis after respiratory infections ( ex. Influenza, RSV and COVID-19). An intramuscular injection may potentially prevent multi-organ damages.

Mullti ogrgan damage (2).jpg

How Does It Work?

   Propriety Gene vectors

​

  • SCARLLEXA and FIBREXA are formulations of an effective transport vehicle  (viral vector)

  • Programmed with the genetic code for a lactoferrin derived anti-scarring peptide. 

  • Applied under the skin before wound closure after surgery or burn injuries  (SCARLEXA) or (FIBREXA) inhaled after respiratory infections such as Influenza, RSV or COVID 19, delivers the genetic code for an anti-scarring peptide to the targeted cells.

  • May Enable continuous production of anti-scarring peptides in the cells of the wound area for many weeks or months.

  • May Help mitigate hyper immune response (cytokine storm), excessive fibrin formation, secondary infections and excessive scar/ fibrosis formation.

​​

 

​​   The peptide disrupts root causes of scarring

​

Inflammation.jpg
Antiinfective 2.png
FIBRINOLYSIS SCARRING.jpg

  •  Inflammation promotes severe scarring

  •  Bottom:  Blocked fibrinolysis promotes scarring. 

  •  Top: Reduced blocking increases fibrinolysis and scar resolution

  • Infections cause inflammation which increases scar formation

bottom of page